<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:e5c4fe34-3348-440e-8249-485360864b3e,g:8feb4d27-f894-4eca-86a5-af804be697f6,d:07e27d50c25e4b6d93ab9f0757bf38bc--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sppi-20220621</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY180L2ZyYWc6YjE1MDNjZTk5YmUzNDIxZjg4OWRmZDdlOGNmNWM1NzIvdGFibGU6NWU4NDI0YmVlZjFkNDcwZDk4ZmI5ZmIxNDI5YmUyN2IvdGFibGVyYW5nZTo1ZTg0MjRiZWVmMWQ0NzBkOThmYjlmYjE0MjliZTI3Yl8yLTEtMS0xLTM1Mzc2_b65ecdb1-78c6-4391-a970-9789aa39b40a">false</ix:nonNumeric><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY180L2ZyYWc6YjE1MDNjZTk5YmUzNDIxZjg4OWRmZDdlOGNmNWM1NzIvdGFibGU6NWU4NDI0YmVlZjFkNDcwZDk4ZmI5ZmIxNDI5YmUyN2IvdGFibGVyYW5nZTo1ZTg0MjRiZWVmMWQ0NzBkOThmYjlmYjE0MjliZTI3Yl8zLTEtMS0xLTM1Mzc2_512e1146-540f-4757-804f-4155fdb203f9">0000831547</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sppi-20220621.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000831547</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-21</xbrli:startDate><xbrli:endDate>2022-06-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i07e27d50c25e4b6d93ab9f0757bf38bc_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGV4dHJlZ2lvbjozNzNhOTYzMWI5ZTI0MmQ4OWJmNWRjNmVkZjE3OGM1ZV8xNjE5_b0a5ac13-34d6-4924-8031-eaa4f2b7e866">8-K</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGV4dHJlZ2lvbjozNzNhOTYzMWI5ZTI0MmQ4OWJmNWRjNmVkZjE3OGM1ZV8yMzg_e64930e2-ae18-4546-8a8c-c61a4957dae8">June 21, 2022</ix:nonNumeric> </span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGV4dHJlZ2lvbjozNzNhOTYzMWI5ZTI0MmQ4OWJmNWRjNmVkZjE3OGM1ZV8xNjIz_fc70a5a3-6d88-4e29-820e-188d50fdf57d">SPECTRUM PHARMACEUTICALS INC</ix:nonNumeric> </span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGFibGU6ZGU5ZmUyMjZkNWY1NDc2MmE2MDhjOThmZmMyNGM5Y2YvdGFibGVyYW5nZTpkZTlmZTIyNmQ1ZjU0NzYyYTYwOGM5OGZmYzI0YzljZl8wLTAtMS0xLTM1Mzc2_3e5dc406-1ea2-4b7d-887a-4c13059007ec">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGFibGU6ZGU5ZmUyMjZkNWY1NDc2MmE2MDhjOThmZmMyNGM5Y2YvdGFibGVyYW5nZTpkZTlmZTIyNmQ1ZjU0NzYyYTYwOGM5OGZmYzI0YzljZl8wLTEtMS0xLTM1Mzc2_f1701b4e-a1ba-44fc-a189-b57a5089f11d">001-35006</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGFibGU6ZGU5ZmUyMjZkNWY1NDc2MmE2MDhjOThmZmMyNGM5Y2YvdGFibGVyYW5nZTpkZTlmZTIyNmQ1ZjU0NzYyYTYwOGM5OGZmYzI0YzljZl8wLTItMS0xLTM1Mzc2_47e4eea5-8649-45ab-a716-6f654769c898">93-0979187</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction <br/>of incorporation)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission <br/>File Number)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer <br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGFibGU6NDNiZGM3NmFjMThlNGMyNGI5NWM2MWY3NzM3MGEzMzIvdGFibGVyYW5nZTo0M2JkYzc2YWMxOGU0YzI0Yjk1YzYxZjc3MzcwYTMzMl8wLTAtMS0xLTM1Mzc2_17895f86-e100-493c-96a2-eb30f714b0fb">11500 South Eastern Avenue</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGFibGU6NDNiZGM3NmFjMThlNGMyNGI5NWM2MWY3NzM3MGEzMzIvdGFibGVyYW5nZTo0M2JkYzc2YWMxOGU0YzI0Yjk1YzYxZjc3MzcwYTMzMl8wLTEtMS0xLTM1Mzc2_66c2b6b4-537f-46e9-9237-06090f8d195a">Suite 220</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGFibGU6NDNiZGM3NmFjMThlNGMyNGI5NWM2MWY3NzM3MGEzMzIvdGFibGVyYW5nZTo0M2JkYzc2YWMxOGU0YzI0Yjk1YzYxZjc3MzcwYTMzMl8wLTItMS0xLTM1Mzc2_a4558af8-9161-4ab2-a63e-e80bb43bfb74">Henderson</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGFibGU6NDNiZGM3NmFjMThlNGMyNGI5NWM2MWY3NzM3MGEzMzIvdGFibGVyYW5nZTo0M2JkYzc2YWMxOGU0YzI0Yjk1YzYxZjc3MzcwYTMzMl8wLTMtMS0xLTM1Mzc2_4a109c1e-10de-4567-836d-dc443955e0c9">Nevada</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGFibGU6NDNiZGM3NmFjMThlNGMyNGI5NWM2MWY3NzM3MGEzMzIvdGFibGVyYW5nZTo0M2JkYzc2YWMxOGU0YzI0Yjk1YzYxZjc3MzcwYTMzMl8wLTQtMS0xLTM1Mzc2_ba9eb7d3-6739-4430-80bd-6775d1dc56db">89052</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGV4dHJlZ2lvbjozNzNhOTYzMWI5ZTI0MmQ4OWJmNWRjNmVkZjE3OGM1ZV8xNjIw_e9c9adf9-b250-4b3e-9010-418d01a283b8">702</ix:nonNumeric>) <ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGV4dHJlZ2lvbjozNzNhOTYzMWI5ZTI0MmQ4OWJmNWRjNmVkZjE3OGM1ZV8xNjI0_db2adf46-99c5-4391-a26a-15c87b2f8e53">835-6300</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address if changed since last report.)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGV4dHJlZ2lvbjozNzNhOTYzMWI5ZTI0MmQ4OWJmNWRjNmVkZjE3OGM1ZV8xNjI1_0a1201ba-0f73-49e3-acce-5177eb5d62a7">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGV4dHJlZ2lvbjozNzNhOTYzMWI5ZTI0MmQ4OWJmNWRjNmVkZjE3OGM1ZV8xNjIx_fafe3873-876e-4f5f-bd07-2396b31d1903">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGV4dHJlZ2lvbjozNzNhOTYzMWI5ZTI0MmQ4OWJmNWRjNmVkZjE3OGM1ZV8xNjIy_61e8643c-1584-4f25-8a41-72ad20233bc9">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGV4dHJlZ2lvbjozNzNhOTYzMWI5ZTI0MmQ4OWJmNWRjNmVkZjE3OGM1ZV8xNjE3_dfb42fe5-2bec-4086-9a32-7b0316366a41">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div style="margin-bottom:6pt;margin-top:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGFibGU6ZjcyMjFmNjg5ZGE1NGQwOWFjNTQ2OTExOTMxM2IyNGUvdGFibGVyYW5nZTpmNzIyMWY2ODlkYTU0ZDA5YWM1NDY5MTE5MzEzYjI0ZV8xLTAtMS0xLTM1Mzc2_21704d4d-7b9f-4a0b-93ac-75058da14574">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGFibGU6ZjcyMjFmNjg5ZGE1NGQwOWFjNTQ2OTExOTMxM2IyNGUvdGFibGVyYW5nZTpmNzIyMWY2ODlkYTU0ZDA5YWM1NDY5MTE5MzEzYjI0ZV8xLTEtMS0xLTM1Mzc2_8db3bff5-90db-4caf-99cf-b09c9bb896c0">SPPI</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGFibGU6ZjcyMjFmNjg5ZGE1NGQwOWFjNTQ2OTExOTMxM2IyNGUvdGFibGVyYW5nZTpmNzIyMWY2ODlkYTU0ZDA5YWM1NDY5MTE5MzEzYjI0ZV8xLTItMS0xLTM1Mzc2_2e7410b2-2c82-4565-b8db-532817f4e84a">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).   Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1d5bcb8c44134c3eb00494b3bb52962b_D20220621-20220621" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjA3ZTI3ZDUwYzI1ZTRiNmQ5M2FiOWYwNzU3YmYzOGJjL3NlYzowN2UyN2Q1MGMyNWU0YjZkOTNhYjlmMDc1N2JmMzhiY18xL2ZyYWc6MzczYTk2MzFiOWUyNDJkODliZjVkYzZlZGYxNzhjNWUvdGV4dHJlZ2lvbjozNzNhOTYzMWI5ZTI0MmQ4OWJmNWRjNmVkZjE3OGM1ZV8xNjE4_9f92bea9-8c64-4637-9ad9-3a3a44f6e926">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i07e27d50c25e4b6d93ab9f0757bf38bc_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:115%">Item 5.02(e)&#160;&#160;&#160;&#160;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">At the Annual Meeting of Stockholders of Spectrum Pharmaceuticals, Inc. (the &#8220;Company&#8221;) held on June 21, 2022 (the &#8220;Annual Meeting&#8221;), the Company&#8217;s stockholders approved an amendment and restatement of the Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan (the &#8220;2018 Plan&#8221;), to increase the number of shares of the Company&#8217;s common stock authorized for issuance thereunder by 18,000,000, from 18,000,000 shares to 36,000,000 shares, plus any shares of the Company&#8217;s common stock that become eligible for issuance under the 2018 Plan because of forfeited awards under the Company&#8217;s 2009 Incentive Award Plan, and to extend the termination date of the 2018 Plan from June 18, 2030 to January 26, 2032. The material terms of the 2018 Plan are summarized in the Company&#8217;s Proxy Statement for the Annual Meeting, filed with the U.S. Securities and Exchange Commission on April 27, 2022 (the &#8220;Proxy Statement&#8221;). A copy of the 2018 Plan is filed as Exhibit 10.1 hereto and is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">Item 5.07   Submission of Matters to a Vote of Security Holders.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">The Company held the Annual Meeting at the Company&#8217;s research and development East office located at 2 Atlantic Avenue, 6th Floor, Boston, Massachusetts 02110.  As of the close of business on April 25, 2022, the record date for the Annual Meeting, a total of 179,257,485 shares were outstanding and entitled to vote, of which a total of 101,771,066 shares were present in person or by proxy at the Annual Meeting, constituting a quorum for the conduct of business thereat.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">The following sets forth detailed information regarding the voting results at the Annual Meeting for each of the matters voted upon by the stockholders.  These matters are described in more detail in the Proxy Statement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:144%;text-decoration:underline">Proposal No. 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:144%">:</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">The Company&#8217;s stockholders elected each of the six nominees named below to serve on the Board of Directors of the Company for a one-year term expiring at the annual meeting of stockholders in 2023 and until their respective successors are duly elected and qualified, or until their earlier resignation or removal.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.231%"><tr><td style="width:1.0%"></td><td style="width:29.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Nominee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Votes For</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Votes Against</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Abstentions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Broker Non-Votes</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">William L. Ashton</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">64,388,175</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">5,000,999</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">340,647</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">32,041,245</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Brittany K. Bradrick</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">65,299,992</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">4,045,297</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">384,532</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">32,041,245</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Seth H.Z. Fischer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">61,153,774</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">8,195,858</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">380,189</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">32,041,245</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Juhyun Lim</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">64,400,566</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">4,951,235</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">378,020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">32,041,245</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Thomas J. Riga</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">65,140,731</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">4,134,182</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">454,908</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">32,041,245</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">Jeffrey L. Vacirca, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">64,278,891</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">5,095,463</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">355,467</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">32,041,245</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:144%;text-decoration:underline">Proposal No. 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:144%">:</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">The Company&#8217;s stockholders approved by advisory vote the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.405%"><tr><td style="width:1.0%"></td><td style="width:18.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Votes For</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Votes Against</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Abstentions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:38.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Broker Non-Votes</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">63,336,099</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">5,934,207</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">459,515</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:38.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">32,041,245</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:144%;text-decoration:underline">Proposal No. 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:144%">:</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">The Company&#8217;s stockholders approved the proposed Amended and Restated Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.405%"><tr><td style="width:1.0%"></td><td style="width:18.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Votes For</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Votes Against</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Abstentions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:38.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Broker Non-Votes</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">63,108,740</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">6,215,120</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">405,961</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:38.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">32,041,245</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:144%;text-decoration:underline">Proposal No. 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:144%">:</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">The Company&#8217;s stockholders ratified the selection of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.405%"><tr><td style="width:1.0%"></td><td style="width:18.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Votes For</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Votes Against</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Abstentions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:38.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:112%;text-decoration:underline">Broker Non-Votes</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">98,912,930</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">2,325,050</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:39pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">533,086</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;text-indent:38.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">0</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:144%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:144%">(d) Exhibits</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit No.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%;text-decoration:underline">Description</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">10.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="spectrumpharmaceuticals201.htm">Amended and Restated Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">104&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;C</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">over Page Interactive Data File, formatted in Inline Extensible Business Reporting Language</span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">(iXBRL)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i07e27d50c25e4b6d93ab9f0757bf38bc_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:7.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:7.5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:137.25pt;padding-right:137.25pt;text-align:center;text-indent:-20.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">SPECTRUM PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">June 23, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">/s/ Keith M. McGahan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Keith M. McGahan <br/>Executive Vice President, Chief Legal Officer and Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "sppi-20220621.htm", "description": "8-K", "secsgml_size_bytes": 54561}]
{"company-data": {"conformed-name": "SPECTRUM PHARMACEUTICALS INC", "cik": "0000831547", "assigned-sic": "2834", "irs-number": "930979187", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35006", "film-number": "221036207"}, "business-address": {"street1": "11500 S. EASTERN AVE., SUITE 240", "city": "HENDERSON", "state": "NV", "zip": "89052", "phone": "702-835-6300"}, "mail-address": {"street1": "11500 S. EASTERN AVE., SUITE 240", "city": "HENDERSON", "state": "NV", "zip": "89052"}, "former-company": [{"former-conformed-name": "NEOTHERAPEUTICS INC", "date-changed": "19960819"}, {"former-conformed-name": "AMERICUS FUNDING CORP", "date-changed": "19920703"}]}
sppi-20220621
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_______________
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 21, 2022
SPECTRUM PHARMACEUTICALS INC
(Exact name of registrant as specified in its charter)
Delaware
001-35006
93-0979187
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
11500 South Eastern Avenue
Suite 220
Henderson
Nevada
89052
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code:
(
702
)
835-6300
Not Applicable
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value
SPPI
The NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02(e)    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
At the Annual Meeting of Stockholders of Spectrum Pharmaceuticals, Inc. (the "Company") held on June 21, 2022 (the "Annual Meeting"), the Company's stockholders approved an amendment and restatement of the Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan (the "2018 Plan"), to increase the number of shares of the Company's common stock authorized for issuance thereunder by 18,000,000, from 18,000,000 shares to 36,000,000 shares, plus any shares of the Company's common stock that become eligible for issuance under the 2018 Plan because of forfeited awards under the Company's 2009 Incentive Award Plan, and to extend the termination date of the 2018 Plan from June 18, 2030 to January 26, 2032. The material terms of the 2018 Plan are summarized in the Company's Proxy Statement for the Annual Meeting, filed with the U.S. Securities and Exchange Commission on April 27, 2022 (the "Proxy Statement"). A copy of the 2018 Plan is filed as Exhibit 10.1 hereto and is incorporated herein by reference.
Item 5.07   Submission of Matters to a Vote of Security Holders.
The Company held the Annual Meeting at the Company's research and development East office located at 2 Atlantic Avenue, 6th Floor, Boston, Massachusetts 02110.  As of the close of business on April 25, 2022, the record date for the Annual Meeting, a total of 179,257,485 shares were outstanding and entitled to vote, of which a total of 101,771,066 shares were present in person or by proxy at the Annual Meeting, constituting a quorum for the conduct of business thereat.
The following sets forth detailed information regarding the voting results at the Annual Meeting for each of the matters voted upon by the stockholders.  These matters are described in more detail in the Proxy Statement.
Proposal No. 1
:
The Company's stockholders elected each of the six nominees named below to serve on the Board of Directors of the Company for a one-year term expiring at the annual meeting of stockholders in 2023 and until their respective successors are duly elected and qualified, or until their earlier resignation or removal.
Nominee
Votes For
Votes Against
Abstentions
Broker Non-Votes
William L. Ashton
64,388,175
5,000,999
340,647
32,041,245
Brittany K. Bradrick
65,299,992
4,045,297
384,532
32,041,245
Seth H.Z. Fischer
61,153,774
8,195,858
380,189
32,041,245
Juhyun Lim
64,400,566
4,951,235
378,020
32,041,245
Thomas J. Riga
65,140,731
4,134,182
454,908
32,041,245
Jeffrey L. Vacirca, M.D.
64,278,891
5,095,463
355,467
32,041,245
Proposal No. 2
:
The Company's stockholders approved by advisory vote the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement.
Votes For
Votes Against
Abstentions
Broker Non-Votes
63,336,099
5,934,207
459,515
32,041,245
Proposal No. 3
:
The Company's stockholders approved the proposed Amended and Restated Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan.
Votes For
Votes Against
Abstentions
Broker Non-Votes
63,108,740
6,215,120
405,961
32,041,245
Proposal No. 4
:
The Company's stockholders ratified the selection of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2022.
Votes For
Votes Against
Abstentions
Broker Non-Votes
98,912,930
2,325,050
533,086
0
Item 9.01    Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
10.1
Amended and Restated Spectrum Pharmaceuticals, Inc. 2018 Long-Term Incentive Plan
.
104        C
over Page Interactive Data File, formatted in Inline Extensible Business Reporting Language
(iXBRL)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SPECTRUM PHARMACEUTICALS, INC.
Date:
June 23, 2022
By:
/s/ Keith M. McGahan
Keith M. McGahan
Executive Vice President, Chief Legal Officer and Secretary